04.06.21

Oxurion Enters Into a Capital Commitment of Up to €30 Million With Negma Group

Source: Oxurion

09.01.20

Oxurion NV Reports First Patient Dosed in Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)

Source: Oxurion NV

08.03.20

Oxurion Appoints Grace Chang, MD, PhD, as Chief Medical Officer

Source: Oxurion

10.09.19

Oxurion NV to Provide Business and Clinical Update at AAO and OIS Meetings in San Francisco

Source: Oxurion NV

09.10.19

Oxurion Reports Additional Positive Topline Data from Phase 1 With THR-149, a Novel, Potent Plasma Kallikrein Inhibitor for DME

Source: Oxurion NV

09.03.19

Oxurion to Make a Late-Breaker Presentation of Topline THR-149 Phase 1 Clinical Data at EURETINA

Source: Oxurion

07.01.19

Oxurion NV Reports Topline Phase 1 Results with THR-149 for the treatment of DME

Source: Oxurion NV

04.24.19

Oxurion Announces Full Enrollment in its Phase 1 Trial Evaluating the Safety of its Plasma Kallikrein Inhibitor THR-149 for Treatment of DME

Source: Oxurion NV

05.25.18

ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149 for Treatment of DME

Source: ThromboGenics

View more stories